Sangamo Therapeutics Shares Sinks After Pfizer Pulls Out of Potential Hemophilia A Therapy Study

MT Newswires Live
2024-12-31

Sangamo Therapeutics (SGMO) was plunging 49% in extended trading, after saying Monday it will regain full development and commercialization rights for giroctocogene fitelparvovec after Pfizer (PFE) decided to terminate the collaboration and licensing agreement for the prospective hemophilia A gene therapy.

The partnership between Sangamo and Pfizer will formally end on April 21, 2025, Sangamo said. It plans on exploring all options to continuing to advance the program, including finding a new collaboration partner.

The companies will also continue to monitor participants in a phase 3 trial of drug candidate during the transition period, it said.

Pfizer shares were fractionally lower in the after-hours session.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10